{"as_of":"2026-08-18T02:33:00Z","caps":{"database_statements":6,"inbound":100,"outbound":100},"context_digest":"sha256:0a68ae5434669960cf129a04fc90509f4a31b5e5cc833c6834a3c84dce4a37f4","coverage":[{"denominator":92,"lane":"reference_resolution","note":"Typed states for the displayed outbound observations.","records_observed":92,"source":"paper_references, paper_reference_links","source_observed_at":"2026-08-10T21:27:31.403799Z","state":"measured"},{"denominator":92,"lane":"standing_notices","note":"One-hop event checks from named stored sources.","records_observed":92,"source":"scholarly_work_events, retraction_status_cache","source_observed_at":"2026-08-17T06:30:58.91139+00:00","state":"measured"},{"denominator":0,"lane":"inbound_itemization","note":"Pith citing papers itemized under the disclosed page cap.","records_observed":0,"source":"paper_references, paper_reference_links","source_observed_at":null,"state":"measured"},{"denominator":1,"lane":"external_citation_measurements","note":"A source-named dated measurement, never combined with another source.","records_observed":0,"source":"cited_works","source_observed_at":null,"state":"measured"}],"external_citation_measurements":[],"inbound":[],"links":{"evidence":"/evidence","html":"/paper/2501.04869/citation-record","integrity":"/paper/2501.04869/integrity","json":"/paper/2501.04869/citation-record.json","paper":"/paper/2501.04869"},"outbound":[{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.881763Z","title":null,"venue":null,"work_id":null,"year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":1,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.881763Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:4f126843f0751383e7637b040977e3f0ec4a9db56926547b5ab288c9202b72ff","observation_id":"ef6e53f8-e74f-4258-9325-9b2e9c2f90c7","resolution":{"observed_at":"2026-08-10T21:27:30.881763Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.886847Z","title":null,"venue":null,"work_id":null,"year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":2,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.886847Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:2a3789fdce369038950f3217e003d378a3c2e587b00f74ed9ae3635339cb2f62","observation_id":"9803165d-9bed-4ec0-a710-457640f0388e","resolution":{"observed_at":"2026-08-10T21:27:30.886847Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.891626Z","title":"A., Lheureux, S","venue":null,"work_id":null,"year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":3,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.891626Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:4fc1ed37f0b08964ff079ebfabb425af01beaacfb3f59912abe806255860cafe","observation_id":"21d482b8-acd5-48ca-b509-bf42b8e31598","resolution":{"observed_at":"2026-08-10T21:27:30.891626Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.896562Z","title":null,"venue":null,"work_id":null,"year":2011},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":4,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.896562Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:98158868e7d0b14354c31c75e01c44b5772be35d14b38edee75dd24593a73830","observation_id":"deb67ed8-37fb-4fc2-90d0-489e9592fc9b","resolution":{"observed_at":"2026-08-10T21:27:30.896562Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.901227Z","title":"& Singh, H","venue":null,"work_id":null,"year":2013},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":5,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.901227Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:a7e86c04a50a098869a10711aa363b61b866a189b75eef0ae519c575ac9a51c6","observation_id":"3af357a1-2813-4393-b9a0-a935141ee290","resolution":{"observed_at":"2026-08-10T21:27:30.901227Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.906406Z","title":null,"venue":null,"work_id":null,"year":2011},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":6,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.906406Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:1b1b0ae03789dc919fc106c2ccc038ba28ad17f4a23e8346ce9356207fc7d332","observation_id":"cbab77f3-ddb0-4dcb-99be-4a007b510c87","resolution":{"observed_at":"2026-08-10T21:27:30.906406Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.911995Z","title":null,"venue":null,"work_id":null,"year":2013},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":7,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.911995Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:0c8e8f31260b209ac692af741b6a26a9050a49d81415bac4be4bc0578f69b291","observation_id":"5e0e9a47-7ec9-4512-b905-c221dd0c22a8","resolution":{"observed_at":"2026-08-10T21:27:30.911995Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.916858Z","title":null,"venue":null,"work_id":null,"year":2014},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":8,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.916858Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:e706ec103344a19a34bf4b2f62e932e67357a98d64f2c5d4893ab380bb5e54e5","observation_id":"e69c7a21-1e54-45e7-9b0d-975b5d9f9f29","resolution":{"observed_at":"2026-08-10T21:27:30.916858Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.921620Z","title":null,"venue":null,"work_id":null,"year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":9,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.921620Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:804027ebcf5729127d0cddc99c4f27fb34ddc2f7f477d9d9c2f2464118cdc08a","observation_id":"bdf09ba5-22c3-444d-b235-13eba37d13cd","resolution":{"observed_at":"2026-08-10T21:27:30.921620Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.926242Z","title":null,"venue":null,"work_id":null,"year":2017},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":10,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.926242Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:daa2e94edcc7b972f0af11d14ee7bbf32c56e305fbc51a5008c6163340bc91f6","observation_id":"23021321-5321-44cb-99df-5e30ab24847d","resolution":{"observed_at":"2026-08-10T21:27:30.926242Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.931104Z","title":null,"venue":null,"work_id":null,"year":2016},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":11,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.931104Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:65e3eaefaadf915b0655b384a7af11a30e0953dde1b2a041e1678fb749fff19d","observation_id":"eab659e9-c3a1-4679-85f3-221affa38680","resolution":{"observed_at":"2026-08-10T21:27:30.931104Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:30.937216Z","title":null,"venue":null,"work_id":null,"year":2019},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":12,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.937216Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:3de2a6cfcf16fb5b81cf05d0beb0dc16916fc2b55ce46d064c6916a4aafeaf11","observation_id":"ea5fba5c-3084-407e-b6bf-fe5abd710fae","resolution":{"observed_at":"2026-08-10T21:27:30.937216Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:33.097134Z","title":null,"venue":null,"work_id":"b757bd8d-bfac-49c7-a2d5-e331f917893d","year":2017},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":13,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.942091Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:38d30a9288a461f35e81a2fd72412cb43376d5f374bad4056efee792cd97b777","observation_id":"73549ca6-8ff9-46b6-9b6a-71804358db9f","resolution":{"observed_at":"2026-08-10T21:27:33.102655Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:33.079348Z","title":null,"venue":null,"work_id":"cc6eff6e-4f3c-4615-b23a-f5acf72519e8","year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":14,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.946999Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:d5815832ab14ec274492b3f1a27c61769525c7fbde803b99a9832f6436acde6c","observation_id":"0a10bd6a-01c1-48a9-b471-86bc9a2bf6fe","resolution":{"observed_at":"2026-08-10T21:27:33.085526Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:33.064085Z","title":null,"venue":null,"work_id":"830a2f12-a648-42f9-b8e8-ca869bfbf3d3","year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":15,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.952291Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:510c20dda74b7fc50cabf9930ea89e213a233943cc94fa46f7b11ef9924766d4","observation_id":"7687e46e-02cb-483f-b998-d78442f486be","resolution":{"observed_at":"2026-08-10T21:27:33.068681Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:33.048747Z","title":null,"venue":null,"work_id":"c55b1e52-f327-43df-9e7a-2e03d24b9d7b","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":16,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.956941Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:559c7770e9e69e5a9853d7b9381616e04c083be40eff42739fe2b25bc825b26c","observation_id":"88122647-e0b0-43f7-8d6c-8826153929c6","resolution":{"observed_at":"2026-08-10T21:27:33.053670Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:33.031193Z","title":null,"venue":null,"work_id":"957f4fa4-f158-49f2-a615-725dec1758bf","year":2017},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":17,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.963163Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:e0b0771d98830e1f24b72c220fba0d72e02d2d824b4dff8b2bbf4cba4299252c","observation_id":"f5251c6c-6d30-47d6-9c4b-fcbb114dc690","resolution":{"observed_at":"2026-08-10T21:27:33.037336Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:33.005452Z","title":null,"venue":null,"work_id":"ebd7ef88-3cd0-412d-a52f-a3c8804b1698","year":2021},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":18,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.968245Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:559fd3a8d5fce5079e011594ca58920ca3e49f6043abb444f3aca33ca3ebed2d","observation_id":"767eb712-ee88-4349-a03a-5f5960ee49d0","resolution":{"observed_at":"2026-08-10T21:27:33.011010Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.978403Z","title":null,"venue":null,"work_id":"517c6256-4d77-4146-baeb-130f33ea19f1","year":2018},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":19,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.973231Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:4f92edef1416bd88effcb96fc7fa3b847cc31d3725eec4232c60456fe3b7498d","observation_id":"9d301eb5-8bc2-4245-b1dc-435e78a6ff92","resolution":{"observed_at":"2026-08-10T21:27:32.984893Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.961908Z","title":null,"venue":null,"work_id":"5d1b8c81-5ae7-44cc-b73a-a6aa515e8614","year":2014},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":20,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.978802Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:3337fc1e190a84d6d27dd27e99ab581857edbb999837ff89b7fd97337e9fa97f","observation_id":"fc1a684c-2b42-41a6-8b4c-f7c65423155b","resolution":{"observed_at":"2026-08-10T21:27:32.966993Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.944337Z","title":null,"venue":null,"work_id":"00e08616-2a43-45f6-a67a-77cfdae17d69","year":2013},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":21,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.985277Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:9b659d2a756f72c5c20488b3eb461f3bb9dbc8108e23fee14888fb385ca8e2b1","observation_id":"ab239c9c-740d-44c5-a1ea-4f363e1f3096","resolution":{"observed_at":"2026-08-10T21:27:32.950229Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.917851Z","title":null,"venue":null,"work_id":"7a215b8b-c3c9-41d1-b15b-c7278af99c18","year":2011},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":22,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.990545Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:36a0904008a405877b18c2e68492b6260d64c296af97ceee4399e479839e2bfb","observation_id":"5340f234-e6ba-41d9-b2b5-db80cdb77da6","resolution":{"observed_at":"2026-08-10T21:27:32.925909Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.900290Z","title":"Integrated genomic analyses of ovarian carcinoma","venue":null,"work_id":"c1f5bd87-7283-438e-885d-650674a560c2","year":2011},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":23,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:30.998302Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:09c355330a02ea274608d3707c1efe4f4fcd47ce4f8c4b143505a48457ce6655","observation_id":"36b9a2b2-3ac3-4b23-a778-214c0f960e2d","resolution":{"observed_at":"2026-08-10T21:27:32.905447Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.872793Z","title":null,"venue":null,"work_id":"e93924f5-59f1-4fe1-98ca-7a76b5a32df2","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":24,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.004817Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:2b8cc5047a23f9bd079bfec4e3b285ee30196873301b760876fe510bb3c3591f","observation_id":"04bda3a6-8c22-461a-8780-ed37540339ab","resolution":{"observed_at":"2026-08-10T21:27:32.878161Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.48550/arxiv.2408.00200","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.603473Z","title":null,"venue":null,"work_id":"8e55cbcc-0f94-4e93-b617-1ed1398d582c","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":25,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.010587Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:62cf10671fc2ef2aed8ba183c86c0ad3cd877c45e9cc37a50856ddd17188f93c","observation_id":"a0abf5af-6ca5-41c6-8f9e-24f2d59fac20","resolution":{"observed_at":"2026-08-10T21:27:31.610077Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.855703Z","title":"& Usdin, T","venue":null,"work_id":"dd0f78e3-b174-4e8a-9542-34690daa58a3","year":2002},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":26,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.016131Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:cdf64673e94f9241ffa6c553747674aeee8383edaab64c0f1550714fe669728f","observation_id":"befbb95f-8d64-46e5-af93-1b766034fa09","resolution":{"observed_at":"2026-08-10T21:27:32.860990Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.736805Z","title":null,"venue":null,"work_id":"0ff9a5a1-23b7-4f21-9c57-271ff2f31c83","year":2012},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":27,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.021045Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:6e65d67e6f92cfe949d6ac5319b5a1d88baa7771534a88edbf38a3ad3f930c22","observation_id":"7493f077-0b2b-4274-9cf0-e83f3e907a01","resolution":{"observed_at":"2026-08-10T21:27:32.843255Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.720438Z","title":null,"venue":null,"work_id":"4ea92e54-d2af-4690-b2ef-3e752c10fd38","year":2021},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":28,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.027325Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:dc4d8d4f9fa8bb4298695175c9a07ccf45a961c141154f2ed4881e6b9f6d0cc6","observation_id":"4daf6554-b873-4be3-860e-b0951db92296","resolution":{"observed_at":"2026-08-10T21:27:32.725788Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.704633Z","title":null,"venue":null,"work_id":"9546461b-8853-49b6-8d6d-ec7b57d2f492","year":2017},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":29,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.033259Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:a8b89e09b0022084c54c55fb32581d91fbe5623d86c068194acdcd7420b00920","observation_id":"5520ee96-0640-484f-9166-39e8b0de29ab","resolution":{"observed_at":"2026-08-10T21:27:32.709664Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.689386Z","title":null,"venue":null,"work_id":"79c9dfc0-dc23-4b7a-adaf-5a9cc0f94bb2","year":1994},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":30,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.039101Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:9961f2ae492999c47e12a9a96309489418c39e9e75ec6d232f754821e8ec6078","observation_id":"47b7ac79-9a81-45e6-a6e9-27ac3eee01cc","resolution":{"observed_at":"2026-08-10T21:27:32.693951Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.673506Z","title":null,"venue":null,"work_id":"0a220f88-93d1-4a86-a083-317435eaf04b","year":2014},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":31,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.044458Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:b38c33c9d69b875b925027836c71b5cc61b3f4edc5275c726768dd755238aa26","observation_id":"3dcbd8e5-f8ad-4437-9337-8f35bc5a3cb8","resolution":{"observed_at":"2026-08-10T21:27:32.678582Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.657085Z","title":"& Lili, F","venue":null,"work_id":"29ef25b8-7504-4cf5-bed6-ea3974bace0a","year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":32,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.050022Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:b4850bea920c955248b6f05d9a7449bd89fe772837a41550270838468bc15f37","observation_id":"fdb82780-7192-4a02-82fd-dd62222c7b0d","resolution":{"observed_at":"2026-08-10T21:27:32.662506Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.639907Z","title":null,"venue":null,"work_id":"39b2d5a2-2b54-46c5-9813-e1836fc3f5ec","year":2015},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":33,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.055111Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:69575f45abbf79bf0a7e5692189395f283d425be2baf4525d8c9714062d3dbb5","observation_id":"20ef85dc-7775-4fca-a7df-cb5c30be012e","resolution":{"observed_at":"2026-08-10T21:27:32.645543Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.622666Z","title":null,"venue":null,"work_id":"59302723-e62e-4abb-a206-b4aeec2416c2","year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":34,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.059708Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:50ffe025204f723036900871750d1018f5e913fae1aace8bec74a118c5d226a7","observation_id":"79a19b41-3361-41ea-96bb-d8291de5b989","resolution":{"observed_at":"2026-08-10T21:27:32.628065Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.605372Z","title":"& Guo, Z","venue":null,"work_id":"a1a63527-1222-41cf-a046-f3a47261818c","year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":35,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.064629Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:04d6088eb58446f094b1e829247917a1161db3091a9cf1cdd5873db12176a0f2","observation_id":"1e0b1922-6e10-48f8-9af9-297b727b0dc0","resolution":{"observed_at":"2026-08-10T21:27:32.610805Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.587984Z","title":"& Dehghani, H","venue":null,"work_id":"7664f757-61ec-4cce-a8ef-15d149d7542a","year":2018},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":36,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.069445Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:e0c8bbeadf78728f27346d137c0872c5c71c64acda9f20f1ecab5ce7dad4359b","observation_id":"a8370f1e-d6fb-41d7-92b8-368bdad09ea5","resolution":{"observed_at":"2026-08-10T21:27:32.592805Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.569580Z","title":"& Benhattar, J","venue":null,"work_id":"b2b4b804-de55-4a2e-933b-0f9d62ab9507","year":2014},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":37,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.074390Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:b1ead9acc6926aac3b1d92109372360e53ff44ce23ac5604320393784ae2e352","observation_id":"4088a7ec-f499-4e06-9a2c-5170ac041845","resolution":{"observed_at":"2026-08-10T21:27:32.575521Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.552070Z","title":null,"venue":null,"work_id":"c8ac32a5-e33d-4811-9c19-5c0e20c8b8ce","year":2019},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":38,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.078837Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:545691ed405abfe0939949b1fa99ecebd7ddce16ebf9ce7baa10d34a2cd18798","observation_id":"001ffd4a-f447-4994-b353-a43ada42d1f3","resolution":{"observed_at":"2026-08-10T21:27:32.557527Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.530596Z","title":null,"venue":null,"work_id":"13bdb580-59a2-4a30-864e-34d03801dee3","year":2015},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":39,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.083342Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:d673b91727cd926b7cbf963baba10ee7dcfb870413203a487973565674524e4d","observation_id":"90c3006e-4554-400d-b624-1f1554f48b8f","resolution":{"observed_at":"2026-08-10T21:27:32.538500Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.512234Z","title":null,"venue":null,"work_id":"26742f61-491f-4e09-b881-401a0336c698","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":40,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.088223Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:7b6546eed283869d73c337582e687ab6a87c90cc51accf53b63f6e4f0d26f438","observation_id":"5333e0e6-789e-4ec7-8304-65ab897025a8","resolution":{"observed_at":"2026-08-10T21:27:32.518245Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.491215Z","title":null,"venue":null,"work_id":"c8eebc18-8c5f-421d-bbb1-a19376e46cc8","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":41,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.093398Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:ec33ee8edd43373651c6ae237113e2ac656e20d7b36215a731fb4cdb02ac8975","observation_id":"2c95bebf-079a-4ec0-b2c0-8de203f86bf9","resolution":{"observed_at":"2026-08-10T21:27:32.496227Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.475015Z","title":"& Soto-Reyes, E","venue":null,"work_id":"e3e6d752-1810-46ab-acc3-833d1e55e7b0","year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":42,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.098593Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:5297b87ce2160917fa854c63168e15fbc94c594487d932b0c3a1bd0270641f5e","observation_id":"4f775161-b5e1-41b0-8c6e-0fc403cf93f3","resolution":{"observed_at":"2026-08-10T21:27:32.479935Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.459206Z","title":null,"venue":null,"work_id":"ef54c38a-e96f-4762-8197-69ab50d5f9a1","year":2019},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":43,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.104623Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:866f62005733e1e6d39ad04929513fb1fd97b603879316c8d462b6dce2d6b52a","observation_id":"0bf8c1a9-60e4-4032-8bf0-aa5e5d9ec3d0","resolution":{"observed_at":"2026-08-10T21:27:32.464097Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.444746Z","title":null,"venue":null,"work_id":"96f4efab-1aaf-4716-b508-fa78e755b004","year":2008},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":44,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.110910Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:a85adcb43f91fdde62dfc6902e67be823c7018068b0a1c85c3dc261d8dd7b366","observation_id":"79f953f4-e7af-4ee3-bdc4-6b3f51787397","resolution":{"observed_at":"2026-08-10T21:27:32.449093Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.429875Z","title":null,"venue":null,"work_id":"2c8064fb-5a08-4022-a38a-1473f5d2cf71","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":45,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.116394Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:1895a310420690940e1441fd28556571bddb2ab97d67b0616b5122fae8d630b4","observation_id":"ed829f74-16fd-49b6-9d73-f4cb92cb2a2e","resolution":{"observed_at":"2026-08-10T21:27:32.434791Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.410666Z","title":null,"venue":null,"work_id":"5724fcb2-5b31-4dd6-bdc9-b55328e527c6","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":46,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.127106Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:138538f3f2a12a4dfe8bd3bfce6a5e72a53438d2376d20a548e872bf5ba63202","observation_id":"10fb97de-9b7a-4004-ab01-f76398282910","resolution":{"observed_at":"2026-08-10T21:27:32.416382Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.388773Z","title":null,"venue":null,"work_id":"da70a69d-c840-48aa-a71e-b2b52eaa5208","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":47,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.132798Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:8680fc34e8f1eeb77893fc2bad728eaebd8e97d003309202db5f1beb74a777a4","observation_id":"df442673-2ddd-452f-a8ed-e802d59a8ec3","resolution":{"observed_at":"2026-08-10T21:27:32.394261Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.366763Z","title":null,"venue":null,"work_id":"86403dfa-73f1-4b34-85ea-5162579da1d3","year":2001},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":48,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.139041Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:3567891edb321f028291f613f035e4121e965144c8bdb1943a55241b7a96d34c","observation_id":"72f103a3-82b8-4355-a094-cf644dd1058e","resolution":{"observed_at":"2026-08-10T21:27:32.372710Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.346175Z","title":null,"venue":null,"work_id":"f9c7d2d3-0ea1-4dab-aa70-ab7cc81e17ce","year":2012},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":49,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.145121Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:74f3b4e55f2e58ad6fc532261762255b23af472801c44d316e53815428d241cc","observation_id":"90a340e4-b9c3-490c-a1ec-2b58b68fcc76","resolution":{"observed_at":"2026-08-10T21:27:32.353291Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.327524Z","title":null,"venue":null,"work_id":"b6158e60-2b74-4c0f-a465-2e486059f98a","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":50,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.150382Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:87ccfa793ad55ae71a449f72a6b76655ae0aed114f13d61a4d80bb3fb6882a2c","observation_id":"bcdbae50-300c-483e-a068-f918a4489b17","resolution":{"observed_at":"2026-08-10T21:27:32.333133Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.305108Z","title":null,"venue":null,"work_id":"f0f6633c-f9b5-4fa1-bea1-337f4f3ead2f","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":51,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.155149Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:4ee3c0cdc769e5707ca2ef0998079ea9105777acded4e41f9666df4031115c87","observation_id":"44b040da-7eef-4da6-984b-ca77b6837da8","resolution":{"observed_at":"2026-08-10T21:27:32.316254Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.289599Z","title":null,"venue":null,"work_id":"3f506d68-8303-432b-b89c-01352eef1aca","year":2018},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":52,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.160937Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:70a36c3fa5a47d71b3783304ae2e252ab20421813af11d4a45536767338f3774","observation_id":"515bbbc9-a4b7-40fb-a161-295d737403d1","resolution":{"observed_at":"2026-08-10T21:27:32.294429Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.274404Z","title":null,"venue":null,"work_id":"e5979537-2fd8-4af0-8461-c246cebe5b56","year":2019},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":53,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.166595Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:4108139a8c7e26fd6643f5a2a83ec9434428cb91d5b19ebb723e942d0a92772e","observation_id":"cf22b2ab-c1bc-44b9-85d7-dc27c83aa566","resolution":{"observed_at":"2026-08-10T21:27:32.279367Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.257219Z","title":null,"venue":null,"work_id":"2c0b30c7-cc3f-4b07-8e79-1378ea51d500","year":2012},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":54,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.171729Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:a80c02c4bd1debb1d46738cf235e75b22e057ce1f8968183750f7e6732b9ed80","observation_id":"040b7a5a-c50a-420e-aec2-1ce7c10ff033","resolution":{"observed_at":"2026-08-10T21:27:32.263044Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.240511Z","title":null,"venue":null,"work_id":"8642f853-6974-4109-99c5-6442d7d09eb3","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":55,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.178515Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:239c7492d8afc98c8795c0b16273e47fa508a6c3480114ab7a46652be0ca9281","observation_id":"05e7fa08-ad7b-4dd7-a32e-05ea6279ca3c","resolution":{"observed_at":"2026-08-10T21:27:32.246001Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.218825Z","title":"& Helfrich, I","venue":null,"work_id":"b708ec07-0a90-47f8-bca2-fa82137cf75e","year":2014},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":56,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.184515Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:de6d2cc2331563b297b68902d2a1f40c27ee408c6e87388f12cd0298f75a55c5","observation_id":"501d7a23-09dc-4759-bd46-f9bb5e191133","resolution":{"observed_at":"2026-08-10T21:27:32.225025Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.198133Z","title":null,"venue":null,"work_id":"ee8fb93b-e3e7-45b3-9422-4378fa3fd128","year":1997},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":57,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.189856Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:c8c10917b155a273e94a2dd20394a318aea59f73a7c96bd6119732f88f1c073b","observation_id":"96b37e1a-830d-43b5-a017-a726c7a29f3a","resolution":{"observed_at":"2026-08-10T21:27:32.204263Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.180692Z","title":null,"venue":null,"work_id":"5324442e-c3cb-47eb-830f-b9e0a7e77026","year":2009},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":58,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.195549Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:de44e8841b28d276290d4bfd16e68c4564063cbd0975f2b0207fc87a567bdd28","observation_id":"badee20e-4558-4965-8279-87583ee5cf02","resolution":{"observed_at":"2026-08-10T21:27:32.185687Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.163303Z","title":"Targeting CTCFL/BORIS for the immunotherapy of cancer","venue":null,"work_id":"7b8c701a-ed2b-451d-b260-122c085bb7db","year":2018},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":59,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.201236Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:7f114bf901fb59af94485e9c70d1c1c3a157f509a978c1f3301414e5a2550fa5","observation_id":"efeb9cd6-9690-42de-bbf0-2938824a09c6","resolution":{"observed_at":"2026-08-10T21:27:32.169739Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.147950Z","title":null,"venue":null,"work_id":"42b7d597-31cb-4304-9e8b-cb475f95c9a8","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":60,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.211171Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:7b4c3a74910b713a1138d69cfe162a8668123cba961cfb4e100d336b73b2ad01","observation_id":"49044cd4-b6e8-4e11-b6bc-4e1035a13cac","resolution":{"observed_at":"2026-08-10T21:27:32.152796Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.133042Z","title":null,"venue":null,"work_id":"35d86712-c3ae-4500-b543-b5de6165d09c","year":2011},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":61,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.217732Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:eed3fe735933317f55fa1ab3518426c2ad78d5f03af77c786903e02f6cf8d46a","observation_id":"e29e5341-3b51-45b5-9c45-cb9d3670c889","resolution":{"observed_at":"2026-08-10T21:27:32.137844Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.116412Z","title":null,"venue":null,"work_id":"92d600c3-2ffd-4251-b423-e2d7c6aac52d","year":2017},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":62,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.224750Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:5cb6f82b009a16cc17cda7113ef3e9abccbc193f371533f57e344efc1bded900","observation_id":"bd3ae781-171d-4291-b390-e311ca57b61e","resolution":{"observed_at":"2026-08-10T21:27:32.121253Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.099460Z","title":null,"venue":null,"work_id":"a44c3a85-e4ec-4cf5-b022-869d4012a1a5","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":63,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.229772Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:14255664ac105553aaf671b572be129218afebd5682d61f7e70ae6b5b9811f50","observation_id":"9419e846-2b4b-4f29-9c59-dbb32167fa6a","resolution":{"observed_at":"2026-08-10T21:27:32.104827Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.082942Z","title":null,"venue":null,"work_id":"20baf624-4b38-41e5-9473-6d92a4d9e492","year":2018},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":64,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.235088Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:070a4cab7bd667d3a3c827822f34af07a716772dc057e4bd0ff1476d6cd8a81b","observation_id":"21ebf3d5-3b5e-4d4c-bb38-8423bdc89926","resolution":{"observed_at":"2026-08-10T21:27:32.087913Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.067245Z","title":null,"venue":null,"work_id":"60af4e1a-3890-47eb-baeb-79e40ee48bd0","year":2013},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":65,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.240441Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:a030ae993c122f15224c6922f77f6c01a264b5f0ccdfddf0efd6163debda4559","observation_id":"0fa37103-0664-4fc8-8962-0610398a2055","resolution":{"observed_at":"2026-08-10T21:27:32.072187Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.049904Z","title":"& Huber, W","venue":null,"work_id":"59eef9e8-d9ab-4f9e-8b8c-e34a9dc792c7","year":2010},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":66,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.248027Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:86563895d72f0382023c9448ceece0ed4019dcf926660daceb1cd34ec2a44c3d","observation_id":"a95e4697-47e8-424a-9c41-b552e76969d7","resolution":{"observed_at":"2026-08-10T21:27:32.055407Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.031994Z","title":"I., Huber, W","venue":null,"work_id":"96c2fad4-1378-401b-83c4-b4680836efce","year":2014},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":67,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.257237Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:32eb3b8290874dbf9a5d57bebe5d596322cd8147f261afc68a56448d825a36ce","observation_id":"520a273c-e2fb-4077-bb33-2c60bdba85a3","resolution":{"observed_at":"2026-08-10T21:27:32.037628Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:32.013289Z","title":null,"venue":null,"work_id":"94fe0a43-b4c0-4ac7-958f-36b2ef1dcb82","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":68,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.263846Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:9ed51f44bd12efa6e5fb6349b6fa9545fc692a3f7d589827161a834a92bfc0e5","observation_id":"236112fe-911d-4581-8ff3-b1de1075af51","resolution":{"observed_at":"2026-08-10T21:27:32.019978Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.990154Z","title":null,"venue":null,"work_id":"8712492e-9bdb-47b7-bd31-33578ceff395","year":2013},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":69,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.272095Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:84dda661e7992d3ee0edb4e89f9445fa64f0e4857f70205b1187c284ae4290a3","observation_id":"73344a09-daa6-4843-9f81-8806e7f2208b","resolution":{"observed_at":"2026-08-10T21:27:31.995034Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.973544Z","title":"B., Blackstone, E","venue":null,"work_id":"f84c6887-c79b-4fe4-abf4-e045683615e5","year":2008},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":70,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.277895Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:f99fbef1298fc8ecfe228b85918c5aa7296e01839d3229b97ec64064b0a86441","observation_id":"b065e08b-90ae-4cf2-a27a-552bb8ffe090","resolution":{"observed_at":"2026-08-10T21:27:31.978794Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.956483Z","title":"scikit-survival: A Library for Time-to-Event Analysis Built on Top of scikit-learn","venue":null,"work_id":"150cb478-6624-476c-b3c7-8b5165f66860","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":71,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.283521Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:ef0584369ff79c3de3f2b75f46d203406df56400dc275c345b73ea3cad62db63","observation_id":"627a938c-86dc-4a09-b3bd-642b33e1cf2d","resolution":{"observed_at":"2026-08-10T21:27:31.962165Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.938296Z","title":"Random Forests","venue":null,"work_id":"79175bdc-74b8-4780-ab09-b978f6d2a0a9","year":2001},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":72,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.289072Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:ffdf355a21934995abfbd69d78d822236a3c9a34ba9c3ed57fe8fb4acb6a878b","observation_id":"5583a36e-75af-44c3-a8b8-65197fbccb96","resolution":{"observed_at":"2026-08-10T21:27:31.944413Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.914672Z","title":"lifelines: survival analysis in Python","venue":null,"work_id":"b8e4d8e0-076e-4e3e-858c-1c5a5abaeec7","year":2019},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":73,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.295493Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:242b8d84c3a8124b33e61edd30305164f1b9351ddc397adb5fb3137cb04c4b78","observation_id":"80e75b89-035e-4ca3-a14f-e6c8542f697a","resolution":{"observed_at":"2026-08-10T21:27:31.919975Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.898464Z","title":null,"venue":null,"work_id":"5ed1d581-3b80-4a91-a61a-9e19bb32855e","year":2015},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":74,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.302559Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:7dd45aa3031b5b40ffc79106db3f26218cdd5a4114464e7db5cd8fc623d88004","observation_id":"3e81ba38-c9de-4224-b4ee-d40ade8dfb98","resolution":{"observed_at":"2026-08-10T21:27:31.903642Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.882731Z","title":"& Peltz, G","venue":null,"work_id":"2a2d7ea4-3248-4a0c-92ad-d546efb78fde","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":75,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.308364Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:11fc55cbe83ca30f2f14b1ccbce1f0e55580bc048805187196e4472763a29c9c","observation_id":"22ef3229-4fd6-4878-8f4a-2f968e925bb4","resolution":{"observed_at":"2026-08-10T21:27:31.887926Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.866981Z","title":null,"venue":null,"work_id":"611bed21-6b43-4194-a1cd-6c94b1d7355e","year":2000},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":76,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.314189Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:17a3eb6fa37841348fb5e1da5fffee5236f606775259a3e941d5c13ab46a2a58","observation_id":"c59c5f22-e43c-45a6-8e70-7d4749b667cc","resolution":{"observed_at":"2026-08-10T21:27:31.872139Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.851119Z","title":"The Gene Ontology knowledgebase in 2023","venue":null,"work_id":"6c6eccc9-2152-49ff-b6a0-a779b62ce1a9","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":77,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.321070Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:28bb3c81d67320e2a4e65c3118fac1438a816f930fec512a3312888e42415969","observation_id":"205101ad-144f-4a29-8201-35a46c4e74b0","resolution":{"observed_at":"2026-08-10T21:27:31.855562Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.836284Z","title":null,"venue":null,"work_id":"c5b3b95b-b337-4274-9d1b-3504a42e9b08","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":78,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.327944Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:b776b5b47f1cee1ccbb08c007df8dd2863938d226059d614970d3cdfb9e89543","observation_id":"a1abfff4-6445-4d6b-a97f-f7b36c9912d9","resolution":{"observed_at":"2026-08-10T21:27:31.840936Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.820320Z","title":null,"venue":null,"work_id":"48a35123-0942-4732-93de-241dcbe13f48","year":2019},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":79,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.334810Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:65496617be0fb860944cefe67d777cc891007f9856618a8c0f49c7c271ff5872","observation_id":"8238969b-e438-4922-84db-4e6db18d3a9d","resolution":{"observed_at":"2026-08-10T21:27:31.825411Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.804295Z","title":"& Ishiguro-Watanabe, M","venue":null,"work_id":"3ade0883-12a1-4da6-a10f-01e5d5583726","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":80,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.340656Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:ff3fdecee9f39896a6b8e29d88d6408cdabcba1ff0db9b506652a947bde90e34","observation_id":"91bc4388-53be-4ea2-a1a9-8993eb0c8d54","resolution":{"observed_at":"2026-08-10T21:27:31.809569Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.787639Z","title":null,"venue":null,"work_id":"2f50402a-3061-4627-8131-2b92e9d682f4","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":81,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.346095Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:6b2ea94e836584795c5e626a3dcc7f07210ce929d68050454245026b5860ac1d","observation_id":"59ba584c-2ddd-491b-a1bd-7931765ee317","resolution":{"observed_at":"2026-08-10T21:27:31.792474Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.771355Z","title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","venue":null,"work_id":"56121738-e763-4edc-bea4-1571baf033c6","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":82,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.353356Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:da32e9d65e7738dad8b42e1a621917385a649510528f023999ae401d901c6442","observation_id":"a4a8aede-b3a4-4d48-bf2f-a6dd226d8db3","resolution":{"observed_at":"2026-08-10T21:27:31.776864Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.754339Z","title":null,"venue":null,"work_id":"4b7abd5f-d1b4-4c3d-994e-fbfe342815ee","year":2020},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":83,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.358695Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:3dbd8637e9eafb22ea2dafffa430653c4240f10bdcb9f9676c4fe9b89dba248a","observation_id":"ebad3fcb-80dc-4fc2-9e90-908f7b75a308","resolution":{"observed_at":"2026-08-10T21:27:31.759813Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.738634Z","title":null,"venue":null,"work_id":"610dfd0f-8a48-41ba-8038-8a5f874ef1fa","year":2023},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":84,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.363910Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:bce871baabe5ad46f6de0dfdb5034e35cc647280368baab45bc3f05f55f62916","observation_id":"4ebf0049-e45f-4eef-9341-4864959ede4e","resolution":{"observed_at":"2026-08-10T21:27:31.743379Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.722157Z","title":"The Tabula Sapiens: A multiple-organ, single-cell transcriptomic atlas of humans","venue":null,"work_id":"e06b0d51-83fc-4f7e-b9e9-4cefc31cdd15","year":2022},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":85,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.369159Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:dc0cd84048bb55b0f1243d1fc1dd8b94cc1b1ca0a6ae0c17568584ebd769e927","observation_id":"350e2e91-5f87-47c3-a5f3-09df3dbe9180","resolution":{"observed_at":"2026-08-10T21:27:31.728097Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.705801Z","title":null,"venue":null,"work_id":"7b6e2a08-da46-42ec-a781-cb2b01e90da9","year":2013},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":86,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.373952Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:1ad0c52e84f0284512971bcc1005a4bce6bd738c11cb140e04ad37d9bc6e7812","observation_id":"bf1ff8e5-2243-4762-a3a7-df489a6b8e06","resolution":{"observed_at":"2026-08-10T21:27:31.711078Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.688415Z","title":"& Hochberg, Y","venue":null,"work_id":"51a9ece8-7414-48d0-a945-cbde6f59b319","year":1995},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":87,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.378899Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:02c1145dc70cf66ecd18fae0d82c1c405df7864307c5ad1b75a8799e6f375a24","observation_id":"f353fd0b-ba0f-4e68-b7bc-319049508c3c","resolution":{"observed_at":"2026-08-10T21:27:31.693668Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.673122Z","title":null,"venue":null,"work_id":"83a230f1-6ea9-4965-bbaa-e80a1f39aa8a","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":88,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.383813Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:9afad2bca5a73db84cb303d0ddff9e31c56a21fdfbd5b07fb5b854ef79bc68ae","observation_id":"38b4e9be-823e-4a07-b899-1f0d060d1629","resolution":{"observed_at":"2026-08-10T21:27:31.677595Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.655825Z","title":null,"venue":null,"work_id":"c1f0575e-3185-49c2-8659-f46f08621024","year":2024},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":89,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.388374Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:1208e588c8583589a282e95100a89cb465782bfb9d3f1337714cc492c4ec8f30","observation_id":"cbe51ddf-7ac6-4415-864e-2421cfdbefac","resolution":{"observed_at":"2026-08-10T21:27:31.660885Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.638337Z","title":null,"venue":null,"work_id":"4946b048-d5be-4f1f-9de1-450e2c361ac0","year":2018},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":90,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.392905Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:048b6a71763ae6a39c8735089427a2a4f200097fcc6928046ce15d28e1894a8c","observation_id":"64ab4aa5-45d3-4ee5-9c91-3b1c03f09924","resolution":{"observed_at":"2026-08-10T21:27:31.643681Z","resolver_source":"raw_fallback","status":"unresolved"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.621768Z","title":"& El-Osta, A","venue":null,"work_id":"0c7ad112-d322-47b0-8805-bb16a622d368","year":2019},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":91,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.397871Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:830c46223d17bbdd6cc4eef39a8f85bb9e9d694325bd8d9cbf3ea7f55d9e3f06","observation_id":"8228d906-45a1-4124-bf48-79ef159bd5bf","resolution":{"observed_at":"2026-08-10T21:27:31.627331Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-17T06:30:58.91139+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T21:27:31.403799Z","title":null,"venue":null,"work_id":null,"year":2016},"citing_paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","version":1},"reference_index":92,"source":"pdf_text","source_observed_at":"2026-08-10T21:27:31.403799Z"},"links":{"citing_paper":"/paper/2501.04869"},"observation_digest":"sha256:dac63d43b04f4b5ed9d920788f0ed16c6ceba10dea638a46f4af21cf12ef501c","observation_id":"31d23ec8-5ffd-43e9-9dfb-87659516a21c","resolution":{"observed_at":"2026-08-10T21:27:31.403799Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}}],"paper":{"arxiv_id":"2501.04869","last_updated":"2025-01-08T22:40:58Z","latest_version":1,"primary_category":"q-bio.GN","snapshot_observed_at":"2026-08-10T23:42:49.677849Z","submitted_at":"2025-01-08T22:40:58Z","title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer"},"reference_resolution":{"displayed":92,"state_counts":{"malformed_identifier":0,"metadata_mismatch":0,"parse_uncertain":0,"unresolved":69,"verified_exact":1,"verified_fuzzy":22},"total_outbound_references":92},"refusal":"A citation records a reference. It does not transfer a finding from one paper to another.","schema":"pith.paper-citation-record.v1","standing_sources":[{"observed_at":"2026-08-17T06:30:58.91139+00:00","source":"crossref"},{"observed_at":"2026-08-17T06:30:54.323127+00:00","source":"retraction_watch"}],"thesis":"As of 18 August 2026, this Paper Citation Record lists 92 of 92 outbound references and 0 inbound Pith citation observations for arXiv:2501.04869."}